Trial Profile
A Pilot, Phase II Study With a Prospective, Randomized, Cross-Over, Placebo-Controlled, Double-Blind Design to Assess the Short-Term Effects of Tolvaptan Plus Placebo vs Tolvaptan Plus Octreotide LAR Combination Therapy in ADPKD Patients With Normal Kidney Function or Hyperfiltration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Octreotide (Primary) ; Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms TOOL
- 01 Feb 2023 Results(n=19 , of week 1- and 4-week treatments) assessing the effects of tolvaptan and octreotide-LAR combination therapy versus those of tolvaptan monotherapy in patients with ADPKD published in the Clinical Journal of The American Society of Nephrology: CJASN
- 10 Mar 2022 Status changed from active, no longer recruiting to completed.
- 05 Oct 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.